Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06250361
Other study ID # GETAID-2023-01
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 15, 2024
Est. completion date June 15, 2025

Study information

Verified date January 2024
Source Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Contact Charlotte Mailhat, PhD
Phone + 33 9 72 57 61 60
Email cmailhat@getaid.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to determine the factors associated with a delayed diagnosis and/or an immediately complicated disease for CD patients. A questionnaire will be completed by the patients, each questionnaire has a patient section and a physician section.


Description:

Number of patients expected : at least 600, coming from all types of practices (ANGH (expert hospitals), GETAID (expert university hospitals) and CREGG (expert private practice)). Recruitment period : 1 year Primary endpoint : The primary endpoint is the description of the factors linked to: - The IBD - The patient (see patient questionnaire in annex 1) - The health care system - The patient's self-care Secondary endpoint : - Validation of the "red flags" in a prospective cohort. - Comparison with the EPIMAD population, especially the location and severity.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 600
Est. completion date June 15, 2025
Est. primary completion date February 15, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Crohn's disease diagnosed less than a year prior to inclusion - Written consent - Age = 18 years Exclusion Criteria: - Diagnosis of Crohn's disease more than one year before inclusion - Patient protected by the law - Patient without health cover

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Questionnaire completion
A questionnaire will be completed by the participant and their gastroenterologist. Estimated completion time is 30 minutes for the patient, 10 minutes for the gastroenterologist.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patient's visits to doctors between the appearance of the first symptoms and the diagnosis of the disease. Number of patient's visits to doctors between the appearance of the first symptoms and the diagnosis of the disease. Day 1 from appearence of first symptoms and the diagnosis of the disease.
Primary Number of exams performed between the appearance of the first symptoms and the diagnosis of the disease. Number of exams performed between the appearance of the first symptoms and the diagnosis of the disease. Day 1 from appearence of first symptoms and the diagnosis of the disease.
Primary Number of medical specialties consulted between the appearance of the first symptoms and the diagnosis of the disease. Number of medical specialties consulted between the appearance of the first symptoms and the diagnosis of the disease. Day 1 from appearence of first symptoms and the diagnosis of the disease.
Secondary Number of predictive factors associated with a delayed diagnosis Number of predictive factors associated with a delayed diagnosis Day 1
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04046913 - The ADDapt Diet in Reducing Crohn's Disease Inflammation N/A
Recruiting NCT05169593 - Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy Phase 4
Recruiting NCT06116604 - Early Bowel Resection for Terminal Ileal Crohn's Disease
Recruiting NCT05294107 - Intestinal Organoids N/A
Recruiting NCT05627128 - A Culturally Tailored Dietary Intervention to Treat Crohn's Disease N/A
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Withdrawn NCT04349449 - ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT03058679 - Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease N/A
Completed NCT02871635 - BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity Phase 3
Recruiting NCT04539665 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease. N/A
Recruiting NCT04266600 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease N/A
Recruiting NCT03913572 - Treatment of Perianal Disease Using Adipose-derived Stem Cells
Completed NCT03668249 - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Completed NCT03606499 - Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
Terminated NCT04102111 - A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease Phase 2
Recruiting NCT04997733 - Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal Phase 3
Recruiting NCT05906576 - Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients Phase 4
Not yet recruiting NCT04398836 - Preoperative Nutrition for Crohn's Disease Patients Phase 3
Not yet recruiting NCT04502303 - 18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease Phase 2